AT 307
Alternative Names: AT-307 - Arecor/Hikma PharmaceuticalsLatest Information Update: 10 Sep 2024
Price :
$50 *
At a glance
- Originator Arecor; Hikma Pharmaceuticals
- Class Peptides; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 10 Sep 2024 Preclinical trials in Unspecified in USA (Parenteral) before September 2024 (Arecor pipeline, September 2024)
- 22 Sep 2022 Early research in Unspecified in USA (Parenteral) (Arecor pipeline, September 2022)
- 22 Sep 2022 Arecor plans to launch AT 307 from 2024 onward (Arecor pipeline, September 2022)